BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35170250)

  • 21. TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection.
    Chen T; Li Q; Zhang X; Long R; Wu Y; Wu J; Fu X
    Hum Pathol; 2018 Sep; 79():93-101. PubMed ID: 29792893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy.
    Yu T; Guo F; Yu Y; Sun T; Ma D; Han J; Qian Y; Kryczek I; Sun D; Nagarsheth N; Chen Y; Chen H; Hong J; Zou W; Fang JY
    Cell; 2017 Jul; 170(3):548-563.e16. PubMed ID: 28753429
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Hussan H; Clinton SK; Roberts K; Bailey MT
    World J Gastroenterol; 2017 Dec; 23(48):8626-8650. PubMed ID: 29358871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic Transformation of Fusobacterium nucleatum.
    Yoshida A; Ikegami A
    Methods Mol Biol; 2021; 2210():43-50. PubMed ID: 32815126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long non-coding RNA EVADR induced by Fusobacterium nucleatum infection promotes colorectal cancer metastasis.
    Lu X; Xu Q; Tong Y; Zhang Z; Dun G; Feng Y; Tang J; Han D; Mao Y; Deng L; He X; Li Q; Xiang Y; Wang F; Zeng D; Tang B; Mao X
    Cell Rep; 2022 Jul; 40(3):111127. PubMed ID: 35858553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain Fusobacterium nucleatum.
    Liu L; Tabung FK; Zhang X; Nowak JA; Qian ZR; Hamada T; Nevo D; Bullman S; Mima K; Kosumi K; da Silva A; Song M; Cao Y; Twombly TS; Shi Y; Liu H; Gu M; Koh H; Li W; Du C; Chen Y; Li C; Li W; Mehta RS; Wu K; Wang M; Kostic AD; Giannakis M; Garrett WS; Hutthenhower C; Chan AT; Fuchs CS; Nishihara R; Ogino S; Giovannucci EL
    Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1622-1631.e3. PubMed ID: 29702299
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Gethings-Behncke C; Coleman HG; Jordao HWT; Longley DB; Crawford N; Murray LJ; Kunzmann AT
    Cancer Epidemiol Biomarkers Prev; 2020 Mar; 29(3):539-548. PubMed ID: 31915144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fusobacterium nucleatum - symbiont, opportunist and oncobacterium.
    Brennan CA; Garrett WS
    Nat Rev Microbiol; 2019 Mar; 17(3):156-166. PubMed ID: 30546113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteomic characterization of outer membrane vesicles from gut mucosa-derived fusobacterium nucleatum.
    Liu J; Hsieh CL; Gelincik O; Devolder B; Sei S; Zhang S; Lipkin SM; Chang YF
    J Proteomics; 2019 Mar; 195():125-137. PubMed ID: 30634002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Replication Study:
    Repass J;
    Elife; 2018 Mar; 7():. PubMed ID: 29533182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knock down of BMSC-derived Wnt3a or its antagonist analogs attenuate colorectal carcinogenesis induced by chronic Fusobacterium nucleatum infection.
    Lin R; Han C; Ding Z; Shi H; He R; Liu J; Qian W; Zhang Q; Fu X; Deng X; Zhou S; Hou X
    Cancer Lett; 2020 Dec; 495():165-179. PubMed ID: 32920199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proinflammatory and Cancer-Promoting Pathobiont
    Cavallucci V; Palucci I; Fidaleo M; Mercuri A; Masi L; Emoli V; Bianchetti G; Fiori ME; Bachrach G; Scaldaferri F; Maulucci G; Delogu G; Pani G
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic Performance of Intestinal
    Peng BJ; Cao CY; Li W; Zhou YJ; Zhang Y; Nie YQ; Cao YW; Li YY
    Chin Med J (Engl); 2018 Jun; 131(11):1349-1356. PubMed ID: 29786050
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Yin H; Miao Z; Wang L; Su B; Liu C; Jin Y; Wu B; Han H; Yuan X
    Aging (Albany NY); 2022 Feb; 14(4):1941-1958. PubMed ID: 35212644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients.
    Kunzmann AT; Proença MA; Jordao HW; Jiraskova K; Schneiderova M; Levy M; Liska V; Buchler T; Vodickova L; Vymetalkova V; Silva AE; Vodicka P; Hughes DJ
    Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1891-1899. PubMed ID: 31367996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment.
    Yu YN; Yu TC; Zhao HJ; Sun TT; Chen HM; Chen HY; An HF; Weng YR; Yu J; Li M; Qin WX; Ma X; Shen N; Hong J; Fang JY
    Oncotarget; 2015 Oct; 6(31):32013-26. PubMed ID: 26397137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fusobacterium nucleatum - Friend or foe?
    Stokowa-Sołtys K; Wojtkowiak K; Jagiełło K
    J Inorg Biochem; 2021 Nov; 224():111586. PubMed ID: 34425476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis in Mice via a Toll-Like Receptor 4/p21-Activated Kinase 1 Cascade.
    Wu Y; Wu J; Chen T; Li Q; Peng W; Li H; Tang X; Fu X
    Dig Dis Sci; 2018 May; 63(5):1210-1218. PubMed ID: 29508166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study of the inflammatory activating process in the early stage of Fusobacterium nucleatum infected PDLSCs.
    Wang Y; Wang L; Sun T; Shen S; Li Z; Ma X; Gu X; Zhang X; Peng A; Xu X; Feng Q
    Int J Oral Sci; 2023 Feb; 15(1):8. PubMed ID: 36754953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fusobacterium nucleatum and oral cancer: a critical review.
    McIlvanna E; Linden GJ; Craig SG; Lundy FT; James JA
    BMC Cancer; 2021 Nov; 21(1):1212. PubMed ID: 34774023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.